These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28872367)

  • 1. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.
    Siemann DW; Chaplin DJ; Horsman MR
    Cancer Invest; 2017 Sep; 35(8):519-534. PubMed ID: 28872367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development and use of vascular targeted therapy in ovarian cancer.
    Chase DM; Chaplin DJ; Monk BJ
    Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
    Close A
    Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
    Horsman MR; Bohn AB; Busk M
    Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AVE8062: a new combretastatin derivative vascular disrupting agent.
    Delmonte A; Sessa C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1541-8. PubMed ID: 19758109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.
    Siemann DW
    Cancer Treat Rev; 2011 Feb; 37(1):63-74. PubMed ID: 20570444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy.
    Wu XY; Ma W; Gurung K; Guo CH
    J Formos Med Assoc; 2013 Mar; 112(3):115-24. PubMed ID: 23473523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of vascular disrupting agents and ionizing radiation.
    Clémenson C; Chargari C; Deutsch E
    Crit Rev Oncol Hematol; 2013 May; 86(2):143-60. PubMed ID: 23177097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular disrupting agents in cancer therapy.
    Smolarczyk R; Czapla J; Jarosz-Biej M; Czerwinski K; Cichoń T
    Eur J Pharmacol; 2021 Jan; 891():173692. PubMed ID: 33130277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular disrupting agents: a new class of drug in cancer therapy.
    Gaya AM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular-disrupting agents in oncology.
    Mita MM; Sargsyan L; Mita AC; Spear M
    Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular toxicity profiles of vascular-disrupting agents.
    Subbiah IM; Lenihan DJ; Tsimberidou AM
    Oncologist; 2011; 16(8):1120-30. PubMed ID: 21742963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
    Head M; Jameson MB
    Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
    Siemann DW; Chaplin DJ; Walicke PA
    Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular damaging agents.
    Patterson DM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of the tumor vasculature.
    Tozer GM; Bicknell R
    Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification and toxicities of vascular disrupting agents.
    Hasani A; Leighl N
    Clin Lung Cancer; 2011 Jan; 12(1):18-25. PubMed ID: 21273175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.